Cancer Lett. 2018 Mar 7;423:9-15. doi: 10.1016/j.canlet.2018.03.005. [Epub ahead of print]
Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
Acquired EGFR T790M mutation; Mutant allele frequency; Non-small cell lung cancer; Primary EGFR T790M mutation; Sensitizing EGFR mutation